Clinical Trial Update: Dalpiciclib in HR+/HER2- ABC

View source ↗

Summary

A clinical trial update shows dalpiciclib is being studied in HR+/HER2- advanced breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: RenJi Hospital | Conditions: Advanced Breast Cancer | Status: RECRUITING